SEC Filing Summary: PerkinElmer, Inc. (Form 10-K)
Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: The filing text identifies the registrant as PerkinElmer, Inc., despite the request metadata referencing "REVVITY, INC.")
Reporting Period: Fiscal year ended December 30, 2007.
Business Overview: A leading provider of technology, services, and solutions to the diagnostics, detection, analysis, and photonics markets. Operations are divided into two segments: Life and Analytical Sciences (instruments, reagents, software for analytical sciences, genetic screening, and BioDiscovery) and Optoelectronics (medical imaging, optical sensors, and specialty lighting).
Employees: Approximately 8,700 as of December 30, 2007.
Key Financial Metrics
| Metric | 2007 (in millions) | 2006 (in millions) |
|---|---|---|
| Total Sales (Continuing Ops) | $1,787.3 | $1,546.4 |
| Operating Income | $168.2 | $153.4 |
| Net Income | $131.7 | $119.6 |
| Diluted EPS (Net Income) | $1.09 | $0.95 |
| Gross Margin | 40.5% | 40.6% |
| Operating Margin | 9.4% | 9.9% |
| Operating Cash Flow | $207.1 | $127.0 |
| Capital Expenditures | $47.0 | $44.5 |
| Total Debt (Long-term + Short-term) | $516.6 | $152.9 |
| Cash and Cash Equivalents | $203.3 | $191.1 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 16% to $1,787.3 million, driven by a 16% increase in Life and Analytical Sciences ($1,327.2M) and a 15% increase in Optoelectronics ($460.1M). Growth was attributed to acquisitions (approx. 4%) and favorable foreign exchange (approx. 4%).
- Acquisitions: Significant activity included the acquisition of ViaCell, Inc. (umbilical cord blood) for approx. $295.8M, Improvision Ltd. ($23.6M), Euroscreen Products S.A. ($18.1M), and Evotec Technologies GmbH ($33.0M).
- Discontinued Operations: The company classified ViaCyte and Cellular Therapy Technology businesses (acquired with ViaCell) as discontinued operations. Additionally, the Fluid Sciences segment (Aerospace, Fluid Testing, Semiconductor) was divested in prior years, with final adjustments impacting 2007 results.
- Restructuring: Incurred $14.4 million in pre-tax restructuring and lease charges in 2007, compared to a $3.6 million reversal in 2006. This included workforce reductions and facility closures.
- Insurance Gain: Recorded a $15.3 million gain from the settlement of an insurance claim related to a 2005 fire at a Boston facility.
- Debt Levels: Long-term debt increased significantly to $516.1 million (from $151.8 million in 2006) due to a $300 million interim credit facility used to finance the ViaCell acquisition.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D spending to increase in 2008. Capital expenditures for 2008 are expected to be similar to 2007 levels. The company anticipates using its revolving credit facility to settle the interim debt in March 2008.
- Leadership Changes: Robert F. Friel was elected CEO effective February 1, 2008. Gregory L. Summe became Executive Chairman.
- Key Risks:
- Market Dependence: Sales are highly dependent on pharmaceutical, biotechnology, and government funding trends.
- International Exposure: 63% of sales are international, exposing the company to currency fluctuations and geopolitical risks.
- Intellectual Property: Significant litigation risks exist, including patent infringement suits involving ViaCell (PharmaStem) and high-throughput screening technologies (Amersham/Enzo).
- Acquisition Integration: Risks associated with integrating acquired businesses and realizing expected synergies.
- Unusual Items: The $15.3 million insurance gain and $14.4 million restructuring charge are non-recurring items affecting operating income.
Investor Verification Checklist
- Debt Maturity: Verify the repayment of the $300 million interim credit facility maturing March 31, 2008, and the impact on liquidity.
- Acquisition Integration: Monitor the integration progress and financial performance of ViaCell and other 2007 acquisitions.
- Legal Contingencies: Track the status of the PharmaStem patent litigation (Supreme Court certiorari petition filed Jan 2008) and the Enzo/Amersham patent disputes.
- Discontinued Operations: Confirm the timeline and financial impact of the planned sale of the ViaCyte and Cellular Therapy Technology businesses.
- Environmental Liabilities: Review the $4.2 million accrued environmental liability and the $5.8 million remaining decommissioning cost for the Boston facility.